The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 31, 2013
Filed:
Dec. 07, 2009
Joseph E. Lynch, Plainfield, NJ (US);
Yuri Y. Bereznitski, South River, NJ (US);
Frederick T. Mattrey, Bridgewater, NJ (US);
John L. Leazer, Jr., Metuchen, NJ (US);
Russell R. Ferlita, Tampa, FL (US);
Jinchu Liu, Edison, NJ (US);
Jungjun Yin, Green Brook, NJ (US);
Robert M. Wenslow, Jr., Cream Ridge, NJ (US);
Joseph E. Lynch, Plainfield, NJ (US);
Yuri Y. Bereznitski, South River, NJ (US);
Frederick T. Mattrey, Bridgewater, NJ (US);
John L. Leazer, Jr., Metuchen, NJ (US);
Russell R. Ferlita, Tampa, FL (US);
Jinchu Liu, Edison, NJ (US);
Jungjun Yin, Green Brook, NJ (US);
Robert M. Wenslow, Jr., Cream Ridge, NJ (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.